Back to News
Market Impact: 0.4
Nyxoah's ACCCESS Trial Of Genio System Meets Primary Goals In CCC Sleep Apnea Patients; Shares Jump
Source: Nasdaq
Healthcare & BiotechCompany FundamentalsCorporate Guidance & Outlook
Nyxoah SA reported positive data from its ACCCESS U.S. pivotal study evaluating the Genio system in adults with moderate-to-severe Obstructive Sleep Apnea (OSA) and Complete Concentric Collapse (CCC). While no effect sizes or endpoints were provided in the excerpt, the update is a constructive regulatory/clinical milestone for the company’s lead technology. The news should be supportive for sentiment around NYXH as it advances toward potential further clinical and approval steps.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
NYXH0.55
More News
- Union Pacific is outperforming this year. UBS says there will be more gains ahead
- Arcee AI trained four models for $20 million. Now, it’s worth $1 billion.
- Premarket movers: Intel jumps on SK Hynix memory-chip talks, J.B. Hunt slides
- AWS says wartime damage means some Middle East cloud resources are gone for good
- Workers at German auto supplier Bosch call for EU action to stem job losses
- Intel’s stock rises as investors hope memory chips can mark the next step in its turnaround